JP2004532806A5 - - Google Patents

Download PDF

Info

Publication number
JP2004532806A5
JP2004532806A5 JP2002542784A JP2002542784A JP2004532806A5 JP 2004532806 A5 JP2004532806 A5 JP 2004532806A5 JP 2002542784 A JP2002542784 A JP 2002542784A JP 2002542784 A JP2002542784 A JP 2002542784A JP 2004532806 A5 JP2004532806 A5 JP 2004532806A5
Authority
JP
Japan
Prior art keywords
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002542784A
Other languages
English (en)
Other versions
JP4387103B2 (ja
JP2004532806A (ja
Filing date
Publication date
Priority claimed from SE0004245A external-priority patent/SE0004245D0/xx
Application filed filed Critical
Priority claimed from PCT/SE2001/002569 external-priority patent/WO2002040456A1/en
Publication of JP2004532806A publication Critical patent/JP2004532806A/ja
Publication of JP2004532806A5 publication Critical patent/JP2004532806A5/ja
Application granted granted Critical
Publication of JP4387103B2 publication Critical patent/JP4387103B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

表1
化合物 Ki(nM)
実施例 2 8
実施例 12 197
実施例 15 616
実施例 18 92
実施例 20 28
実施例 23 478
実施例 32 48
実施例 48 37
JP2002542784A 2000-11-20 2001-11-20 セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物 Expired - Fee Related JP4387103B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0004245A SE0004245D0 (sv) 2000-11-20 2000-11-20 Novel compounds and their use
US25350900P 2000-11-28 2000-11-28
PCT/SE2001/002569 WO2002040456A1 (en) 2000-11-20 2001-11-20 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009148822A Division JP2009280587A (ja) 2000-11-20 2009-06-23 セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物

Publications (3)

Publication Number Publication Date
JP2004532806A JP2004532806A (ja) 2004-10-28
JP2004532806A5 true JP2004532806A5 (ja) 2009-09-17
JP4387103B2 JP4387103B2 (ja) 2009-12-16

Family

ID=26655311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002542784A Expired - Fee Related JP4387103B2 (ja) 2000-11-20 2001-11-20 セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物
JP2009148822A Pending JP2009280587A (ja) 2000-11-20 2009-06-23 セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009148822A Pending JP2009280587A (ja) 2000-11-20 2009-06-23 セロトニン５ｈｔ−２レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物

Country Status (16)

Country Link
EP (1) EP1335907B1 (ja)
JP (2) JP4387103B2 (ja)
KR (1) KR100846339B1 (ja)
CN (1) CN1267424C (ja)
AT (1) ATE470662T1 (ja)
AU (2) AU2426602A (ja)
BR (1) BR0115400A (ja)
CA (1) CA2448729A1 (ja)
DE (1) DE60142355D1 (ja)
HK (2) HK1061855A1 (ja)
IL (2) IL155702A0 (ja)
MX (1) MXPA03004390A (ja)
NO (1) NO325181B1 (ja)
NZ (1) NZ525700A (ja)
PL (1) PL361690A1 (ja)
WO (1) WO2002040456A1 (ja)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
AU2003213184A1 (en) * 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Pyridyl sulfone derivatives as 5-ht receptor antagonists
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
SE0201544D0 (sv) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
US6989392B2 (en) 2002-06-18 2006-01-24 Abbott Laboratories 2-Aminoquinolines as melanin concentrating hormone receptor antagonists
US7226925B2 (en) 2002-06-19 2007-06-05 Biovitrum Ab Compounds, their use and preparation
WO2004000830A1 (en) 2002-06-19 2003-12-31 Biovitrum Ab Novel compounds, their use and preparation
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
GB0215775D0 (en) * 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP5015586B2 (ja) * 2003-01-29 2012-08-29 アステランド ユーケイ リミテッド Ｅｐ４受容体アンタゴニスト
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
WO2005033105A2 (en) * 2003-09-30 2005-04-14 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP4529116B2 (ja) * 2003-10-16 2010-08-25 東レ・ファインケミカル株式会社 高純度トリチルピペラジン誘導体の製造方法
US7476687B2 (en) 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US20080194574A1 (en) * 2003-12-16 2008-08-14 Axxima Pharmaceuticals Ag Pyrazine Derivatives As Effective Compounds Against Infectious Diseases
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
EP1869000A1 (en) 2005-03-31 2007-12-26 Pfizer Products Incorporated Cyclopentapyridine and tetrahydroquinoline derivatives
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
CA2675638C (en) 2007-01-16 2015-11-24 Ipintl, Llc Composition comprising serotonin for treating metabolic syndrome
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
HUE035069T2 (en) * 2011-12-28 2018-05-02 Global Blood Therapeutics Inc Substituted benzaldehyde compounds and their use to increase tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
MX2014014308A (es) * 2012-05-30 2015-02-12 Hoffmann La Roche Pirrolidino heterociclos.
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
PE20161035A1 (es) 2013-03-15 2016-11-13 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulacion de la hemoglobina
KR20150132146A (ko) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CA2903022C (en) 2013-03-15 2021-11-09 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JP6809681B2 (ja) 2014-02-07 2021-01-06 グローバル ブラッド セラピューティクス インコーポレイテッド ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
MX2017016530A (es) 2015-06-22 2018-03-12 Arena Pharm Inc Sal cristalina de l-arginina del acido (r)-2-(7-(4-ciclopentil-3-( trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3- il)acetico (compuesto1) para ser utilizada en transtornos asociados con el receptor de esfingosina-1-fosfato 1 (s1p1).
TW201731509A (zh) 2015-12-04 2017-09-16 全球血液治療公司 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP3982949A4 (en) * 2019-06-14 2023-10-11 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
TW202227417A (zh) 2020-08-18 2022-07-16 美商默沙東藥廠 雙環庚烷吡咯啶之食慾素受體促效劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
IE911774A1 (en) * 1990-06-11 1991-12-18 Akzo Nv Pyridinylpiperazine derivatives
WO1994011363A1 (en) * 1992-11-09 1994-05-26 Asahi Kasei Kogyo Kabushiki Kaisha 2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivative, process for producing the same, and use thereof
JPH07300474A (ja) * 1994-05-02 1995-11-14 Asahi Chem Ind Co Ltd テトラハイドロキノキサリン誘導体およびその用途
FR2761071B1 (fr) * 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
GB9718833D0 (en) * 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
AU754529B2 (en) * 1998-09-22 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Cyanophenyl derivatives
FR2788772B1 (fr) * 1999-01-26 2001-03-02 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK1157005T3 (da) * 1999-02-24 2005-02-14 Hoffmann La Roche 3-phenylpyridinderivater og anvendelsen deraf som NK-1-receptorantagonister

Similar Documents

Publication Publication Date Title
JP2004532806A5 (ja)
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
ATE289796T1 (de) Orale zusammensetzung
NO20041339D0 (no) Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
ATE404528T1 (de) 7,9 substituierte tetracyclinverbindungen
IS6971A (is) Ný efnasambönd
SE0004245D0 (sv) Novel compounds and their use
MXPA03009361A (es) Compuestos de urea utilies como agentes anti-inflamatorios.
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
JP2001354766A5 (ja)
NO20035153L (no) Karbapenemforbindelse
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
ATE478155T1 (de) Glycopeptidantibiotika
TH85054EX (th) ???????????????????????????????????????????????
SE0103802D0 (sv) Novel compound
IS7299A (is) 3,4-díhýdró-1H-ísókínólóín-2-ýl-afleiður
SE0102403D0 (sv) Novel compounds
SE0104473D0 (sv) Novel Compounds
SE0104141D0 (sv) Novel compounds
SE0101617D0 (sv) Novel compounds
SE0200704D0 (sv) Novel compounds
SE0102094D0 (sv) Novel compounds
SE0104472D0 (sv) Novel Compounds
SE0100641D0 (sv) Novel compounds